Skip to main content
SpringerLink
Log in

Diagnosis and Management of Autoimmune Myasthenia Gravis

  • Review Article
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Earlier diagnosis and the availability of effective treatments have reduced the burden of high mortality and severe disability previously associated with myasthenia gravis (MG). Consequently, the prognosis of MG is now much improved. However, despite extensive knowledge of MG and its aetiology, diagnosing the disease remains problematic and can be delayed because of its nonspecific and fluctuating symptoms, and the management of MG is associated with considerable limitations. Current treatments based on immunomodulation are associated with adverse effects arising from prolonged immune suppression. There is a need for improved awareness among primary caregivers about this relatively rare, but treatable, disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Table I

Similar content being viewed by others

References

  1. Tiedt TN, Albuquerque EX, Hudson CS, et al. Neostigmineinduced alterations at the mammalian neuromuscular junction. I. Muscle contraction and electrophysiology. J Pharmacol Exp Ther 1978 May; 205(2): 326–39

    PubMed  CAS  Google Scholar 

  2. Boonyapisit K, Kaminski HJ, Ruff RL. Disorders of neuromuscular junction ion channels. Am J Med 1999 Jan; 106(1): 97–113

    Article  PubMed  CAS  Google Scholar 

  3. Hughes BW, Kusner LL, Kaminski HJ. Molecular architecture of the neuromuscular junction. Muscle Nerve 2006 Apr; 33(4): 445–61

    Article  PubMed  CAS  Google Scholar 

  4. Drachman DB. Myasthenia gravis. N Engl J Med 1994 Jun 23; 330(25): 1797–810

    Article  PubMed  CAS  Google Scholar 

  5. Hoch W, McConville J, Helms S, et al. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001 Mar; 7(3): 365–8

    Article  PubMed  CAS  Google Scholar 

  6. Witzemann V. Development of the neuromuscular junction. Cell Tissue Res 2006 Nov; 326(2): 263–71

    Article  PubMed  Google Scholar 

  7. Harper CM. Congenital myasthenic syndromes. Semin Neurol 2004 Mar; 24(1): 111–23

    Article  PubMed  Google Scholar 

  8. Phillips 2nd LH, Torner JC. Epidemiologic evidence for a changing natural history of myasthenia gravis. Neurology 1996 Nov; 47(5): 1233–8

    Article  PubMed  Google Scholar 

  9. Phillips 2nd H. The epidemiology of myasthenia gravis. Ann N Y Acad Sci 2003 Sep; 998: 407–12

    Article  PubMed  Google Scholar 

  10. Flachenecker P. Epidemiology of neuroimmunological diseases. J Neurol 2006 Sep; 253Suppl. 5: V2–8

    Article  PubMed  Google Scholar 

  11. Thanvi BR, Lo TC. Update on myasthenia gravis. Postgrad Med J 2004 Dec; 80(950): 690–700

    Article  PubMed  CAS  Google Scholar 

  12. Aarli JA. Myasthenia gravis in the elderly: is it different? Ann N Y Acad Sci 2008; 1132: 238–43

    Article  PubMed  Google Scholar 

  13. Aragones JM, Bolibar I, Bonfill X, et al. Myasthenia gravis: a higher than expected incidence in the elderly. Neurology 2003 Mar 25; 60(6): 1024–6

    Article  PubMed  CAS  Google Scholar 

  14. Vincent A, Clover L, Buckley C, et al. Evidence of underdiagnosis of myasthenia gravis in older people. J Neurol Neurosurg Psychiatry 2003 Aug; 74(8): 1105–8

    Article  PubMed  CAS  Google Scholar 

  15. Oosterhuis HJ. The natural course of myasthenia gravis: a long term follow up study. J Neurol Neurosurg Psychiatry 1989 Oct; 52(10): 1121–7

    Article  PubMed  CAS  Google Scholar 

  16. Grob D, Brunner N, Namba T, et al. Lifetime course of myasthenia gravis. Muscle Nerve 2008 Feb; 37(2): 141–9

    Article  PubMed  Google Scholar 

  17. Juel VC, Massey JM. Myasthenia gravis. Orphanet J Rare Dis 2007; 2: 44

    Article  PubMed  Google Scholar 

  18. Kulaksizoglu IB. Mood and anxiety disorders in patients with myasthenia gravis: aetiology, diagnosis and treatment. CNS Drugs 2007; 21(6): 473–81

    Article  PubMed  CAS  Google Scholar 

  19. Myasthenia Gravis Foundation of America. Myasthenia gravis: a manual for the health care provider [online]. Available from URL: http: //www.myasthenia.org/docs/ MGFA_ProfessionalManual.pdf [Accessed 2008 Nov 18]

  20. Barohn RJ, McIntire D, Herbelin L, et al. Reliability testing of the quantitative myasthenia gravis score. Ann N Y Acad Sci 1998 May 13; 841: 769–72

    Article  PubMed  CAS  Google Scholar 

  21. Jaretzki 3rd A, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 2000 Jul 12; 55(1): 16–23

    Article  PubMed  Google Scholar 

  22. Stewart AL, Hays RD, Ware Jr JE. The MOS short-form general health survey: reliability and validity in a patient population. Med Care 1988 Jul; 26(7): 724–35

    Article  PubMed  CAS  Google Scholar 

  23. Burns TM, Conaway MR, Cutter GR, et al. Less is more, or almost as much: a 15-item quality-of-life instrument for myasthenia gravis. Muscle Nerve 2008 Aug; 38(2): 957–63

    Article  PubMed  Google Scholar 

  24. Mullins LL, Carpentier MY, Paul RH, et al. Diseasespecific measure of quality of life for myasthenia gravis. Muscle Nerve 2008 Aug; 38(2): 947–56

    Article  PubMed  Google Scholar 

  25. Padua L, Evoli A, Aprile I, et al. Health-related quality of life in patients with myasthenia gravis and the relationship between patient-oriented assessment and conventional measurements. Neurol Sci 2001 Oct; 22(5): 363–9

    Article  PubMed  CAS  Google Scholar 

  26. Paul RH, Nash JM, Cohen RA, et al. Quality of life and well-being of patients with myasthenia gravis. Muscle Nerve 2001 Apr; 24(4): 512–6

    Article  PubMed  CAS  Google Scholar 

  27. Rostedt A, Padua L, Stalberg EV. Correlation between a patient-derived functional questionnaire and abnormal neuromuscular transmission in myasthenia gravis patients. Clin Neurophysiol 2005 Sep; 116(9): 2058–64

    Article  PubMed  Google Scholar 

  28. Rostedt A, Padua L, Stalberg EV. Correlation between regional myasthenic weakness and mental aspects of quality of life. Eur JNeurol 2006 Feb; 13(2): 191–3

    Article  CAS  Google Scholar 

  29. Magni G, Micaglio GF, Lalli R, et al. Psychiatric disturbances associated with myasthenia gravis. Acta Psychiatr Scand 1988 Apr; 77(4): 443–5

    Article  PubMed  CAS  Google Scholar 

  30. Beekman R, Kuks JB, Oosterhuis HJ. Myasthenia gravis: diagnosis and follow-up of 100 consecutive patients. J Neurol 1997 Feb; 244(2): 112–8

    Article  PubMed  CAS  Google Scholar 

  31. Lindstrom J. An assay for antibodies to human acetylcholine receptor in serum from patients with myasthenia gravis. Clin Immunol Immunopathol 1977 Jan; 7(1): 36–43

    Article  PubMed  CAS  Google Scholar 

  32. Vincent A, Newsom-Davis J. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry 1985 Dec; 48(12): 1246–52

    Article  PubMed  CAS  Google Scholar 

  33. Ohta K, Shigemoto K, Kubo S, et al. MuSK antibodies in AChR Ab-seropositive MG vs AChR Ab-seronegative MG. Neurology 2004 Jun 8; 62(11): 2132–3

    Article  PubMed  CAS  Google Scholar 

  34. Evoli A, Tonali PA, Padua L, et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 2003 Oct; 126 (Pt 10): 2304–11

    Article  PubMed  Google Scholar 

  35. Shigemoto K, Kubo S, Jie C, et al. Myasthenia gravis experimentally induced with muscle-specific kinase. Ann N Y Acad Sci 2008; 1132: 93–8

    Article  PubMed  CAS  Google Scholar 

  36. Martignago S, Fanin M, Albertini E, et al. Muscle histopathology in myasthenia gravis with antibodies against MuSK and AChR. Neuropathol Appl Neurobiol 2009 Feb; 35(1): 103–10

    Article  PubMed  CAS  Google Scholar 

  37. Rostedt Punga A, Ahlqvist K, Bartoccioni E, et al. Neurophysiological and mitochondrial abnormalities in MuSK antibody seropositive myasthenia gravis compared to other immunological subtypes. Clin Neurophysiol 2006 Jul; 117(7): 1434–43

    Article  PubMed  CAS  Google Scholar 

  38. Le Panse R, Cizeron-Clairac G, Cuvelier M, et al. Regulatory and pathogenic mechanisms in human autoimmune myasthenia gravis. Ann N Y Acad Sci 2008; 1132: 135–42

    Article  PubMed  Google Scholar 

  39. Scherer K, Bedlack RS, Simel DL. Does this patient have myasthenia gravis? JAMA 2005 Apr 20; 293(15): 1906–14

    Article  PubMed  CAS  Google Scholar 

  40. Bever Jr CT, Aquino AV, Penn AS, et al. Prognosis of ocular myasthenia. Ann Neurol 1983 Nov; 14(5): 516–9

    Article  PubMed  Google Scholar 

  41. Chaudhuri A, Behan PO. Myasthenic crisis. QJM 2009 Feb; 102(2): 97–107

    Article  PubMed  CAS  Google Scholar 

  42. Panda S, Goyal V, Behari M, et al. Myasthenic crisis: a retrospective study. Neurol India 2004 Dec; 52(4): 453–6

    PubMed  CAS  Google Scholar 

  43. Berrouschot J, Baumann I, Kalischewski P, et al. Therapy of myasthenic crisis. Crit Care Med 1997 Jul; 25(7): 1228–35

    Article  PubMed  CAS  Google Scholar 

  44. Gajdos P, Chevret S, Clair B, et al. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann Neurol 1997 Jun; 41(6): 789–96

    Article  PubMed  CAS  Google Scholar 

  45. Murthy JM, Meena AK, Chowdary GV, et al. Myasthenic crisis: clinical features, complications and mortality. Neurol India 2005 Mar; 53(1): 37–40; discussion 40

    Article  PubMed  CAS  Google Scholar 

  46. Zinman L, Ng E, Bril V. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology 2007 Mar 13; 68(11): 837–41

    Article  PubMed  CAS  Google Scholar 

  47. Luchanok U, Kaminski HJ. Ocular myasthenia: diagnostic and treatment recommendations and the evidence base. Curr Opin Neurol 2008 Feb; 21(1): 8–15

    Article  PubMed  Google Scholar 

  48. Benatar M. A systematic review of diagnostic studies in myasthenia gravis. Neuromuscul Disord 2006 Jul; 16(7): 459–67

    Article  PubMed  Google Scholar 

  49. Vincent A, Leite MI, Farrugia ME, et al. Myasthenia gravis seronegative for acetylcholine receptor antibodies. Ann N Y Acad Sci 2008; 1132: 84–92

    Article  PubMed  CAS  Google Scholar 

  50. Bau V, Hanisch F, Hain B, et al. Ocular involvement in MuSK antibody-positive myasthenia gravis [in German]. Klin Monbl Augenheilkd 2006 Jan; 223(1): 81–3

    Article  PubMed  CAS  Google Scholar 

  51. Cikes N, Momoi MY, Williams CL, et al. Striational autoantibodies: quantitative detection by enzyme immunoassay in myasthenia gravis, thymoma, and recipients of D-penicillamine or allogeneic bone marrow. Mayo Clin Proc 1988 May; 63(5): 474–81

    PubMed  CAS  Google Scholar 

  52. Dumitru D. Part IV, Section 25: Neuromuscular junction disorders: electrodiagnostic medicine. 2nd ed. Philadelphia (PA): Hanley & Belfus, 2001

    Google Scholar 

  53. AAEM Quality Assurance Committee. Practice parameter for repetitive nerve stimulation and single fiber EMG evaluation of adults with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome: summary statement. Muscle Nerve 2001 Sep; 24(9): 1236–8

    Article  Google Scholar 

  54. Howard Jr JF, Sanders DB, Massey JM. The electrodiagnosis of myasthenia gravis and the Lambert-Eaton myasthenic syndrome. Neurol Clin 1994 May; 12(2): 305–30

    PubMed  Google Scholar 

  55. Zivkovic SA, Shipe C. Use of repetitive nerve stimulation in the evaluation of neuromuscular junction disorders. Am J Electroneurodiagnostic Technol 2005 Dec; 45(4): 248–61

    PubMed  Google Scholar 

  56. Stickler DE, Sanders DB. Single-fiber EMG, 2009 [online]. Available from URL: http://emedicine.medscape.com/ article/1141438-overview [Accessed 2010 Mar 9]

  57. Burns TM, Conaway M, Sanders DB. The MG composite: a valid and reliable outcome measure for myasthenia gravis. Neurology 2010 May 4; 74(18): 1434–40

    Article  PubMed  Google Scholar 

  58. Burns TM, Conaway MR, Cutter GR, et al. Construction of an efficient evaluative instrument for myasthenia gravis: the MG composite. Muscle Nerve 2008 Dec; 38(6): 1553–62

    Article  PubMed  Google Scholar 

  59. Genkins G, Sivak M, Tartter PI. Treatment strategies in myasthenia gravis. Ann N Y Acad Sci 1993 Jun 21; 681: 603–8

    Article  PubMed  CAS  Google Scholar 

  60. Walker MB. Treatment of myasthenia gravis with physostigmine. Lancet 1934; 1: 1200–1

    Article  Google Scholar 

  61. McEachern D. Prostigmine in myasthenia gravis. Can Med AssocJ 1935; 310-1

  62. Skeie GO, Apostolski S, Evoli A, et al. Guidelines for the treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2006 Jul; 13(7): 691–9

    Article  PubMed  CAS  Google Scholar 

  63. Havard CW, Fonseca V. New treatment approaches to myasthenia gravis. Drugs 1990 Jan; 39(1): 66–73

    Article  PubMed  CAS  Google Scholar 

  64. Aquilonius SM, Eckernas SA, Hartvig P, et al. Clinical pharmacology of pyridostigmine and neostigmine in patients with myasthenia gravis. J Neurol Neurosurg Psychiatry 1983 Oct; 46(10): 929–35

    Article  PubMed  CAS  Google Scholar 

  65. Schumm F, Gaertner HJ, Wiatr G, et al. Serum levels of pyridostigmine in myasthenia gravis: methods and clinical significance [in German]. Fortschr Neurol Psychiatr 1985 Jun; 53(6): 201–11

    Article  PubMed  CAS  Google Scholar 

  66. Osserman KE. Progress report on mestinon bromide (pyridostigmine bromide).Am J Med 1955 Nov; 19(5): 737–9

    Article  PubMed  CAS  Google Scholar 

  67. Data on file, Meda Group, 2010

  68. eMC. Mestinon (pyridostigmine bromide) 60 mg tablets: summary of product characteristics. 2007 [online]. Available from URL: http://emc.medicines.org.uk/medicine/ 865/SPC/Mestinon+60mg+Tablets/ [Accessed 2009 May 29]

  69. Milner-Brown HS, Mellenthin M, Sharma ML, et al. Quantitative correlation between plasma pyridostigmine levels and neuromuscular function in myasthenia gravis. Neurology 1987 May; 37(5): 800–3

    Article  PubMed  CAS  Google Scholar 

  70. Young WL, Matteo RS, Ornstein E. Duration of action of neostigmine and pyridostigmine in the elderly. Anesth Analg 1988 Aug; 67(8): 775–8

    Article  PubMed  CAS  Google Scholar 

  71. eMC. Neostigmine bromide tablets: summary of product characteristics. 2001 [online]. Available from URL: http:// emc.medicines.org.uk/document.aspx?documentId=384 [Accessed 2009 Apr 6]

  72. eMC. Neostigmine methylsulphate BP 2.5mg in 1mL: summary of product characteristics. 2008 [online]. Available from URL: http://emc.medicines.org.uk/medicine/ 20888/SPC/Neostigmine+Methylsulphate+Injection+BP+ 2.5mg+in+1ml+ (hameln)/ [Accessed 2009 Jun 2]

  73. Schwab RS, Marshall CK, Timberlake W. WIN 8077 in treatment of myasthenia gravis; use of N,N’-bis (2-diethylaminoethyl) oxamide bis-2-chlorobenzyl chloride in fifty patients. J Am Med Assoc 1955 Jun 25; 158(8): 625–8

    Article  PubMed  CAS  Google Scholar 

  74. sanofi-synthelabo. Mytelase® (ambenonium chloride) prescribing information. 2008 July [online]. Available from URL: http://products.sanofi-aventis.us/mytelase/mytelase. html [Accessed 2010 Jun 25]

  75. Pascuzzi RM, Coslett HB, Johns TR. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol 1984 Mar; 15(3): 291–8

    Article  PubMed  CAS  Google Scholar 

  76. Schneider-Gold C, Gajdos P, Toyka KV, et al. Corticosteroids for myasthenia gravis. Cochrane Database Syst Rev 2005; (2): CD002828

  77. Hart IK, Sharshar T, Sathasivam S. Immunosuppressant drugs for myasthenia gravis. J Neurol Neurosurg Psychiatry 2009 Jan; 80(1): 5–6; discussion 6

    Article  PubMed  CAS  Google Scholar 

  78. Palace J, Newsom-Davis J, Lecky B. A randomized doubleblind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology 1998 Jun; 50(6): 1778–83

    Article  PubMed  CAS  Google Scholar 

  79. Hart IK, Sathasivam S, Sharshar T. Immunosuppressive agents for myasthenia gravis. Cochrane Database Syst Rev 2007; (4): CD005224

  80. Tindall RS, Rollins JA, Phillips JT, et al. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med 1987 Mar 19; 316(12): 719–24

    Article  PubMed  CAS  Google Scholar 

  81. Bonifati DM, Angelini C. Long-term cyclosporine treatment in a group of severe myasthenia gravis patients. J Neurol 1997 Sep; 244(9): 542–7

    Article  PubMed  CAS  Google Scholar 

  82. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000 May; 47(2-3): 85–118

    Article  PubMed  CAS  Google Scholar 

  83. Meriggioli MN, Ciafaloni E, Al-Hayk KA, et al. Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. Neurology 2003 Nov 25; 61(10): 1438–40

    Article  PubMed  CAS  Google Scholar 

  84. Sanders DB, Hart IK, Mantegazza R, et al. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology 2008 Aug 5; 71(6): 400–6

    Article  PubMed  CAS  Google Scholar 

  85. Muscle Study Group. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology 2008 Aug 5; 71(6): 394–9

    Article  Google Scholar 

  86. Hehir MK, Burns TM, Alpers JP, et al. Long-term experience with mycophenolate mofetil (MMF) in myasthenia gravis (MG): retrospective analysis of 103 patients [abstract]. Neurology 2009; 72(11 Suppl. 3): A440

    Google Scholar 

  87. Gajdos P, Chevret S, Toyka K. Plasma exchange for myasthenia gravis. Cochrane Database Syst Rev 2002; (4): CD002275

  88. Gajdos P, Chevret S, Toyka K. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev 2008; (1): CD002277

  89. Chan A, Lee DH, Linker R, et al. Rescue therapy with anti-CD20 treatment in neuroimmunologic breakthrough disease. J Neurol 2007 Nov; 254(11): 1604–6

    Article  PubMed  Google Scholar 

  90. Hain B, Jordan K, Deschauer M, et al. Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab. Muscle Nerve 2006 Apr; 33(4): 575–80

    Article  PubMed  Google Scholar 

  91. Thakre M, Inshasi J, Marashi M. Rituximab in refractory MuSK antibody myasthenia gravis. J Neurol 2007 Jul; 254(7): 968–9

    Article  PubMed  Google Scholar 

  92. Sussman JD, Argov Z, McKee D, et al. Antisense treatment for myasthenia gravis: experience with monarsen. Ann N Y Acad Sci 2008; 1132: 283–90

    Article  PubMed  CAS  Google Scholar 

  93. Gronseth GS, Barohn RJ. Thymectomy for myasthenia gravis. Curr Treat Options Neurol 2002 May; 4(3): 203–9

    Article  PubMed  Google Scholar 

  94. Gronseth GS, Barohn RJ. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000 Jul 12; 55(1): 7–15

    Article  PubMed  CAS  Google Scholar 

  95. Aghajanzadeh M, Khoshrang H, Mohammadzadeh A, et al. Thymectomy for myasthenia gravis: prognostic factors in 70 patients. Asian Cardiovasc Thorac Ann 2007 Oct; 15(5): 371–5

    PubMed  Google Scholar 

  96. Abt PL, Patel HJ, Marsh A, et al. Analysis of thymectomy for myasthenia gravis in older patients: a 20-year single institution experience. J Am Coll Surg 2001 Apr; 192(4): 459–64

    Article  PubMed  CAS  Google Scholar 

  97. Tsuchida M, Yamato Y, Souma T, et al. Efficacy and safety of extended thymectomy for elderly patients with myasthenia gravis. Ann Thorac Surg 1999 Jun; 67(6): 1563–7

    Article  PubMed  CAS  Google Scholar 

  98. Sanders DB, El-Salem K, Massey JM, et al. Clinical aspects of MuSK antibody positive seronegative MG. Neurology 2003 Jun 24; 60(12): 1978–80

    Article  PubMed  CAS  Google Scholar 

  99. Magee MJ, Mack MJ. Surgical approaches to the thymus in patients with myasthenia gravis. Thorac Surg Clin 2009 Feb; 19(1): 83–9, vii

    Article  PubMed  Google Scholar 

  100. Pasnoor M, Wolfe GI, Nations S, et al. Clinical findings in MuSK-antibody positive myasthenia gravis: a US experience. Muscle Nerve 2010 Mar; 41(3): 370–4

    Article  PubMed  Google Scholar 

  101. ClinicalTrials.gov. Thymectomy trial in non-thymomatous myasthenia gravis patients receiving prednisone therapy. 2009 November 9 [online]. Available from URL: http://www.clinicaltrials.gov/ct2/show/NCT00294658?term=non-thy momatous&rank=1 [Accessed 2010 Jun 25]

Download references

Acknowledgements

The author thanks Rod McNab and Mary Hines from inScience Communications, a Wolters Kluwer business, who provided medical writing services funded by MEDA Group, Spain. The author also acknowledges the supportive discussions at Eurobiobank (supported by Translational Research in Europe — Assessment and Treatment of Neuromuscular Diseases [TREAT-NMD]) and the support of the Italian Ministry of Education. The author has no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Department of Neurosciences, University of Padova, Via Giustiniani 5, 35128, Padova, Italy

    Corrado Angelini

  2. IRCSS S. Camillo, Venice, Italy

    Corrado Angelini

Authors
  1. Corrado Angelini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Corrado Angelini.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Angelini, C. Diagnosis and Management of Autoimmune Myasthenia Gravis. Clin. Drug Investig. 31, 1–14 (2011). https://doi.org/10.2165/11584740-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11584740-000000000-00000

Keywords

Search

Navigation